Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia

Brian M. Barth, Weiyuan Wang, Paul T. Toran, Todd E. Fox, Charyguly Annageldiyev, Regina M. Ondrasik, Nicole R. Keasey, Timothy J. Brown, Viola G. Devine, Emily C. Sullivan, Andrea L. Cote, Vasiliki Papakotsi, Su Fern Tan, Sriram S. Shanmugavelandy, Tye G. Deering, David B. Needle, Stephan T. Stern, Junjia Zhu, Jason Liao, Aaron D. VinyDavid J. Feith, Ross L. Levine, Hong Gang Wang, Thomas P. Loughran, Arati Sharma, Mark Kester, David F. Claxton

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)2598-2603
Number of pages6
JournalBlood Advances
Volume3
Issue number17
DOIs
StatePublished - Sep 10 2019

ASJC Scopus subject areas

  • Hematology

Cite this

Barth, B. M., Wang, W., Toran, P. T., Fox, T. E., Annageldiyev, C., Ondrasik, R. M., Keasey, N. R., Brown, T. J., Devine, V. G., Sullivan, E. C., Cote, A. L., Papakotsi, V., Tan, S. F., Shanmugavelandy, S. S., Deering, T. G., Needle, D. B., Stern, S. T., Zhu, J., Liao, J., ... Claxton, D. F. (2019). Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. Blood Advances, 3(17), 2598-2603. https://doi.org/10.1182/bloodadvances.2018021295